Jeff Yass’s Milestone Pharmaceuticals MIST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$16.5K Buy
+12,300
New +$19.7K ﹤0.01% 13076
2026
Q1
Sell
-73,200
Closed -$148K 13744
2025
Q4
$148K Sell
73,200
-8,000
-10% -$17.2K ﹤0.01% 11184
2025
Q3
$162K Buy
81,200
+38,300
+89% +$67.3K ﹤0.01% 11206
2025
Q2
$83.2K Sell
42,900
-149,400
-78% -$199K ﹤0.01% 11889
2025
Q1
$154K Buy
192,300
+145,500
+311% +$289K ﹤0.01% 11208
2024
Q4
$110K Buy
+46,800
New +$80.3K ﹤0.01% 11257
2024
Q3
Sell
-16,900
Closed -$22.5K 12621
2024
Q2
$22.5K Buy
+16,900
New +$27.2K ﹤0.01% 11639
2023
Q2
Sell
-13,200
Closed -$52K 12724
2023
Q1
$52K Sell
13,200
-75,500
-85% -$276K ﹤0.01% 11685
2022
Q4
$351K Buy
88,700
+17,300
+24% +$91.1K ﹤0.01% 8716
2022
Q3
$656K Buy
+71,400
New +$542K ﹤0.01% 7733
2022
Q2
Sell
-11,100
Closed -$71K 13546
2022
Q1
$71K Buy
+11,100
New +$69.4K ﹤0.01% 12120
2021
Q4
Sell
-34,600
Closed -$198K 13593
2021
Q3
$198K Sell
34,600
-70,600
-67% -$398K ﹤0.01% 11490
2021
Q2
$579K Buy
105,200
+25,700
+32% +$146K ﹤0.01% 9246
2021
Q1
$460K Buy
+79,500
New +$582K ﹤0.01% 9677

Other funds holding MIST

Jeff Yass's MIST Position: Q2 2026 in Review

Jeff Yass reduced its Milestone Pharmaceuticals (MIST) stake by 31% in Q2 2026, selling an estimated $254K and leaving 359,895 shares worth $482K. The position accounts for ﹤0.01% of the portfolio, ranked #10002.

Jeff Yass first reported a position in MIST in Q4 2020 and has held it in 13 quarters since. The position peaked at $1.3M in Q4 2025. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Jeff Yass held 359,895 shares of Milestone Pharmaceuticals worth $482K as of Q2 2026.
  • Jeff Yass sold 159,151 Milestone Pharmaceuticals shares in Q2 2026, an estimated $254K.
  • Milestone Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10002 holding.
  • Jeff Yass first reported a position in Milestone Pharmaceuticals in Q4 2020 and has held it in 13 quarters since.
  • Jeff Yass's Milestone Pharmaceuticals position peaked at $1.3M in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.